Enabling Continuous Manufacturing For CAR-T And LNP-Based Therapies: The DIANT Pharma Platform

Manufacturing bottlenecks are a significant concern in the fields of particle- and cell-based therapies. Traditional, often manual, downstream processing steps for both LNP purification and CAR-T post-processing can introduce variability and increase contamination risks. DIANT Pharma's continuous manufacturing platform is engineered to address these issues by automating and integrating crucial steps like buffer exchange, concentration, and sterile filtration into a closed, single-use system.

This approach is designed to improve consistency, reduce operational costs, and streamline development timelines, ultimately accelerating the availability of personalized medicine and gene-modified therapies. Uncover how DIANT Pharma is advancing bioprocessing with its scalable and monitored platform. Read the full article to learn more.